20/07/2019 17:00:00

ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important August 5th Deadline in the Securities Class Action – HRTX

NEW YORK, July 20, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Heron Therapeutics, Inc. (NASDAQ: HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”) of the important August 5, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Heron investors under the federal securities laws.

To join the Heron class action, go to https://www.rosenlegal.com/cases-register-1589.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Heron had failed to include adequate Chemistry, Manufacturing, and Controls and non-clinical information in its New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for HTX-011; (2) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (3) as a result, Heron’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1589.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.   Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee future outcomes.

Contact Information:

      Laurence Rosen, Esq.

      Phillip Kim, Esq.

      The Rosen Law Firm, P.A.

      275 Madison Avenue, 34th Floor

      New York, NY 10016

      Tel: (212) 686-1060

      Toll Free: (866) 767-3653

      Fax: (212) 202-3827

      lrosen@rosenlegal.com

      pkim@rosenlegal.com

      cases@rosenlegal.com

      www.rosenlegal.com

Related content
05 Aug - 
MONDAY DEADLINE ALERT: The Schall Law Firm Announces th..
02 Aug - 
Final Deadline: (HRTX) Heron Therapeutics, Inc. - Brons..
02 Aug - 
The Klein Law Firm Reminds Investors of Class Actions o..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
VGP NV: Record Amount of New Lease Contracts Solidifies Path of Continued Future Growth
2
MDxHealth: MDxHealth Notice of Interim Results 2019
3
DCHFA Finances Its Second Deanwood Affordable Rental Community of the Summer
4
SalMar – Results for the second quarter 2019
5
Fellow Finance growth continues according to the company strategy: turnover grew by 29,6%

Related stock quotes

Heron Therapeutics Inc 17.38 -3.9% Stock price decreasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 August 2019 01:59:14
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-24 02:59:14 - 2019-08-24 01:59:14 - 1000 - Website: OKAY